| アブストラクト | BACKGROUND: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials. METHODS: We conducted a follow-up study with a nested case-control analysis using the General Practice Research Database to compare the risk of developing a first-time diagnosis of an eye disorder during exposure of mefloquine, chloroquine and/or proguanil or atovaquone/proguanil use to non-users. We calculated incidence rates with 95% confidence intervals (CI) and odds ratios using multivariate conditional logistic regression analyses. RESULTS: We included 83,148 patients and identified 652 cases with an incident eye disorder. The incidence rates with 95% CI of all eye disorders combined in users of mefloquine, chloroquine and/or proguanil, atovaquone/proguanil or travellers not using anti-malarials were 5.3 (4.3-6.5), 7.1 (5.0-9.9), 6.3 (5.6-7.2) and 5.1 (4.6-5.7), per 1000 person-years, respectively. As compared to non-users of anti-malarials, the adjusted odds ratio with 95% CI in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 1.33 (1.01-1.75), 1.61 (1.06-2.45), and 1.25 (1.03-1.52), respectively. CONCLUSIONS: The study provides evidence that there was an increased risk of eye disorders in users of all anti-malarials compared to non-users of anti-malarials. |
|---|
| ジャーナル名 | Travel medicine and infectious disease |
|---|
| Pubmed追加日 | 2013/9/17 |
|---|
| 投稿者 | Schneider, Cornelia; Adamcova, Miriam; Jick, Susan S; Schlagenhauf, Patricia; Miller, Mary K; Rhein, Hans-Georg; Meier, Christoph R |
|---|
| 組織名 | Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,;Department of Pharmaceutical Sciences, University Basel, Basel, Switzerland.;Electronic address: schneiderc@uhbs.ch.;Safety Risk Management, F. Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic;address: miriam.adamcova@roche.com.;Boston Collaborative Drug Surveillance Program, Boston University School of;Medicine, Lexington, MA, USA. Electronic address: sjick@bu.edu.;University of Zuerich Centre for Travel Medicine, Institute for Social and;Preventive Medicine, Zuerich, Switzerland. Electronic address: pat@ifspm.uzh.ch.;Department of Epidemiology, Genentech Inc., South San Francisco, USA. Electronic;address: miller.katie@gene.com.;address: hans-georg.rhein@roche.com.;Department of Pharmaceutical Sciences, University Basel, Basel, Switzerland;;Medicine, Lexington, MA, USA; Hospital Pharmacy, University Hospital Basel,;Basel, Switzerland. Electronic address: meierch@uhbs.ch. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/24035311/ |
|---|
